Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Crystal Shereen Denlinger, Tara Beth Sanft, Kevin Scott Baker et al. · Journal of the National Comprehensive Cancer Network · 2018
The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for common physical and psychosocial consequences of cancer and cancer treatment to help healthcare professionals who work with survivors of adult-onset cancer in the posttreatment period. This portion of the guidelines describes recommendations regarding the management of anthracycline-induced cardiotoxicity and lymphedema. In addition, recommendations regarding immunizations and the prevention of infections in cancer survivors are included.
Cited by 200 works. doi:10.6004/jnccn.2018.0078
Authors
- Crystal Shereen Denlinger
- Tara Beth Sanft
- Kevin Scott Baker
- Gregory A. Broderick
- Wendy Demark‐Wahnefried
- Debra L. Friedman
- Mindy E. Goldman
- Melissa M. Hudson
- Nazanin Khakpour
- Allison A. King
- Divya T. Koura
- Robin Mary Lally
- Terry S. Langbaum
- Allison L. McDonough
- Michelle Melisko
- José Gilberto Montoya
- Kathi H. Mooney
- Javid J. Moslehi
- Tracey L. O’Connor
- Linda Overholser
References
- 2013 ACCF/AHA Guideline for the Management of Heart Failure
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions
- ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary
- Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
- Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
- Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31
- American College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors